MCMaarten H. L. Christiaans

Maarten H. L. Christiaans

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maarten H. L. Christiaans has a total of 195 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Unveiling Donor-Derived BKPyV DNAemia Through Analysis of Contralateral Kidney Transplant Recipients

    by Wouter T. Moest, A. Lianne Messchendorp, Helma Dolmans, Cynthia Konijn-Janssen, Stan van Den Eijnden, Milou van Bruchem, Ineke Tieken, Maarten H. L. Christiaans, Arjan D. van Zuilen, Marcia M. L. Kho, et al.

    Background: BK polyomavirus (BKPyV) infection is of notable concern in kidney transplant recipients, as it can cause BKPyV-associated nephropathy (BKPyVAN). Currently, there is no effective treatment for BKPyV infection, underscoring the need for preventive strategies. There is emerging evidence that donor-derived BKPyV plays a role in the development of BKPyV DNAemia. To further explore this hypothesis, we conducted a retrospective, multi-center cohort study to evaluate the risk of developing BKPyV DNAemia in kidney recipient pairs sharing the same donor. Methods: At the Leiden University Medical Center (LUMC), deceased donor kidney transplant recipients (2011–2021) were identified and classified according to the occurrence of BKPyV DNAemia within the first year post-transplantation. For each recipient, the contralateral kidney recipient from the same donor was identified through national transplant registries. Cox regression was used to assess whether BKPyV DNAemia in the LUMC recipient was associated with an increased risk of BKPyV DNAemia in the contralateral recipient. Results: Among 117 recipient pairs, BKPyV DNAemia was more frequent when the contralateral recipient was affected (28.8% [15/52]), compared with pairs in which the contralateral recipient remained unaffected (10.8% [7/65], p = 0.013). Multivariable Cox regression analysis confirmed this increased risk (HR 4.9, 95% CI: 1.8–13.6; p = 0.002). Conclusions: This study shows a significantly increased risk of BKPyV DNAemia in recipients of deceased donor kidneys when the contralateral kidney recipient develops BKPyV DNAemia. These findings highlight the influence of donor-derived factors in BKPyV transmission in kidney transplantation.

  • Open Access

    Comparable outcomes for old, older, and very old deceased donors in old kidney transplant recipients

    by Silke E. de Boer, Erzsi Tegzess, Daan Kremer, Frederike J. Bemelman, Maarten H.L. Christiaans, Luuk B. Hilbrands, Aiko P.J. de Vries, Dorottya K. de Vries, Jacqueline van de Wetering, Hendrikus J.A.N. Kimenai, et al.


  • Open Access

    Organ Donor Potential After Extracorporeal Cardiopulmonary Resuscitation for Out‐of‐Hospital Cardiac Arrest: A Post‐Hoc Analysis of a Randomized Controlled Trial

    by Hanne C. R. Verberght, Thijs S. R. Delnoij, Martje M. Suverein, Jody Lunsing, Renicus C. Hermanides, Luuk Otterspoor, Carlos V. Elzo Kraemer, Alexander P. J. Vlaar, Joris J. van der Heijden, Erik Scholten, et al.

    Background: Extracorporeal cardiopulmonary resuscitation (ECPR) is a potentially life‐saving intervention in refractory out‐of‐hospital cardiac arrest (OHCA). ECPR enables, in most of the treated cases, ICU admission to patients who otherwise would have died at the emergency department (ED). Still, many of them die, frequently after withdrawal of life‐sustaining therapies due to irreversible critical conditions and related complications. The additional time provided by ECPR, however, might allow for the assessment of organ donor suitability. The aim of this study was to evaluate the impact of ECPR on the number of potential organ donors after refractory OHCA. Methods: We performed a post‐hoc analysis of the multicenter INCEPTION trial, which randomized 134 OHCA patients between conventional CPR (CCPR) and ECPR. Detailed patient reports were presented to transplant physicians to determine the acceptability of the liver and kidneys for organ donation. In addition to the intention to treat analysis, we performed an “as‐treated” analysis, limited to patients arriving without return of spontaneous circulation (ROSC) at the ED. Results: Out of 70 patients randomized to ECPR and 64 to CCPR, potential organ donors were identified in 14 (20%) and 4 (6%) patients, respectively ( χ 2 test, p = 0.038). In the as‐treated analysis, 15 out of 55 (27%) treated with ECPR were potential donors, compared to 0 out of 59 treated with CCPR ( p < 0.001). This included five (9%) potential kidney donors and 15 (27%) potential liver donors. Conclusion: Although ECPR is currently used with life‐saving intentions, it may simultaneously increase the number of potential organ donors following cardiac arrest in selected patients. Trial Registration: ClinicalTrials.gov identifier: NCT03101787

  • Open Access

    Favorable Living Donor Kidney Transplantation Outcomes within a National Kidney Exchange Program

    by Stijn C. van de Laar, Annelies E. de Weerd, Frederike J. Bemelman, Mirza M. Idu, Aiko P.J. de Vries, Ian P.J. Alwayn, Stefan P. Berger, Robert A. Pol, Arjan D. van Zuilen, Raechel J. Toorop, et al.

    Key Points: KEP recipients have comparable long-term graft survival to direct living donor kidney transplantation recipients, which underscores the need to prioritize KEP over other's therapies. Our outcomes can be achieved regardless of whether the donor travels or the graft is transported, offering flexibility in program implementation. Background: KEPs (kidney exchange programs) facilitate living donor kidney transplantations (LDKTs) for patients with incompatible donors, who are typically at higher risk than non-KEP patients because of higher sensitization and longer dialysis vintage. We conducted a comparative analysis of graft outcomes and risk factors for both KEP and non-KEP living donor kidney transplants. Methods: All LDKTs performed in The Netherlands between 2004 and 2021 were included. The primary outcome measures were 1-, 5-, and 10-year death-censored graft survival. The secondary outcome measures were delayed graft function, graft function, rejection rates, and patient survival. We used a propensity score–matching model to account for differences at baseline. Results: Of 7536 LDKTs, 694 (9%) were transplanted through the KEP. Ten-year graft survival was similar for KEP (0.916; 95% confidence interval, 0.894 to 0.939) and non-KEP (0.919; 0.912 to 0.926, P = 0.82). We found significant differences in 5-year rejection (12% versus 7%) and 5-year patient survival (KEP: 84%, non-KEP: 90%), which was nonsignificant after propensity score matching. Significant risk factors of lower graft survival included high donor age, retransplantations, extended dialysis vintage, higher panel reactive antibodies, and nephrotic syndrome as the cause of ESKD. Conclusions: Transplantation through KEP offers a viable alternative for patients lacking compatible donors, avoiding specific and invasive pre- and post-transplant treatments. KEP's similar survival rate to non-KEPs suggests prioritizing KEP LDKTs over deceased donor kidney transplantation, desensitization, and dialysis. However, clinicians should consider the identified risk factors when planning and managing pre- and post-transplant care to enhance patient outcomes. Thus, we advocate for the broad adoption of KEP and establishment in regions lacking such programs, alongside initiation and expansion of international collaborations.


  • Open Access

    The differential impact of early graft dysfunction in kidney donation after brain death and after circulatory death: Insights from the Dutch National Transplant Registry

    by Thei S. Steenvoorden, Lara Evers, Liffert Vogt, Janneke A.J. Rood, Jesper Kers, Marije C. Baas, Maarten H.L. Christiaans, Jan H.N. Lindeman, Jan-Stephan F. Sanders, Aiko P.J. de Vries, et al.


  • Open Access

    Effect of an exercise intervention or combined exercise and diet intervention on health-related quality of life-physical functioning after kidney transplantation: the Active Care after Transplantation (ACT) multicentre randomised controlled trial

    by Tim J Knobbe, Daan Kremer, Dorien M Zelle, Gerald Klaassen, Desie Dijkema, Iris M Y van Vliet, Paul B Leurs, Frederike J Bemelman, Maarten H L Christiaans, Stefan P Berger, et al.


  • Open Access

    Living Kidney Donor Knowledge of Provided Information and Informed Consent: The PRINCE Study

    by Emerentia Q. W. Spoon, Kirsten Kortram, Sohal Y. Ismail, Daan Nieboer, Frank C. H. D’ancona, Maarten H. L. Christiaans, Ruth E. Dam, Hendrik Sijbrand Hofker, Arjan W. J. Hoksbergen, Karlijn Ami van der Pant, et al.

    Background: Informed consent for living kidney donation is paramount, as donors are healthy individuals undergoing surgery for the benefit of others. The informed consent process for living kidney donors is heterogenous, and the question concerns how well they are actually informed. Knowledge assessments, before and after donor education, can form the basis for a standardized informed consent procedure for live kidney donation. Methods: In this prospective, a multicenter national cohort study conducted in all eight kidney transplant centers in The Netherlands, we assessed the current status of the informed consent practice for live donor nephrectomy. All of the potential living kidney donors in the participating centers were invited to participate. They completed a pop quiz during their first outpatient appointment (Cohort A). Living kidney donors completed the same pop quiz upon admission for donor nephrectomy (Cohort B). Results: In total, 656 pop quizzes were completed (417 in Cohort A, and 239 in Cohort B). The average donor knowledge score was 7.0/25.0 (±3.9, range 0–18) in Cohort A, and 10.5/25.0 (±2.8, range 0–17.5) in Cohort B. Cohort B scored significantly higher on overall knowledge, preparedness, and the individual item scores (p < 0.0001), except for the long-term complications (p = 0.91). Conclusions: Donor knowledge generally improves during the live donor workup, but it is still quite disappointing. Long-term complications, especially, deserve more attention during living kidney donor education.


  • Open Access

    Kidney Transplantation After Rescue Allocation—the Eurotransplant Experience: A Retrospective Multicenter Outcome Analysis

    by Volker Assfalg, Gregor Msc Miller, Felix Stocker, Marieke van Meel, Tiny Groenevelt, Ineke Tieken, Donna Ankerst, Lutz Renders, Alexander Novotny, Daniel Md Hartmann, et al.

    Background.: At Eurotransplant (ET), kidneys are transferred to “rescue allocation” (RA), whenever the standard allocation (SA) algorithms Eurotransplant Kidney Allocation System (ETKAS) and Eurotransplant Senior Program (ESP) fail. We analyzed the outcome of RA. Methods.: Retrospective patient clinical and demographic characteristics association analyses were performed with graft outcomes for 2422 recipients of a deceased donor renal transplantation (DDRT) after RA versus 25 481 after SA from 71 centers across all ET countries from 2006 to 2018. Results.: Numbers of DDRTs after RA increased over the time, especially in Germany. RA played a minor role in ESP versus ETKAS (2.7% versus 10.4%). RA recipients and donors were older compared with SA recipients and donors, cold ischemia times were longer, waiting times were shorter, and the incidence of primary nonfunction was comparable. Among ETKAS recipients, HLA matching was more favorable in SA (mean 3.7 versus 2.5). In multivariate modeling, the incidence of graft loss in ETKAS recipients was reduced in RA compared with SA (subdistribution hazard ratio, 0.80; 95% confidence interval [0.70-0.91], P < 0.001), whereas other outcomes (mortality, death with functioning graft (DwFG)) were not significantly different. None of the 3 outcomes were significantly different when comparing RA with SA within the ESP program. Conclusions.: Facing increased waiting times and mortality on dialysis due to donor shortage, this study reveals encouragingly positive DDRT outcomes following RA. This supports the extension of RA to more patients and as an alternative tool to enable transplantation in patients in countries with prohibitively long waiting times or at risk of deterioration.


  • Open Access

    External validation of a model to predict risk of keratinocyte skin cancer after renal transplantation in a Western European cohort

    by E.J. Verhage, P.J. Nelemans, S.M.J. Kuijk, M.H.L. Christiaans, N.W.J. Kelleners‐Smeets

    Renal transplant recipients (RTRs) face an increased risk of developing keratinocyte skin cancer (KSC) due to their lifelong immunosuppressive drug use. Current recommendations call for 6‐ to 12‐monthly skin examinations for all RTRs. To develop a more personalized screening procedure, Urwin, et al identified the most significant KSC risk factors in an Australian sample and developed a predictive index (PI) that stratifies patients into high‐, medium‐ and low‐risk groups. We have externally validated this PI and evaluated its geographic transportability to The Netherlands.

  • A limited sampling strategy to estimate exposure of once-daily modified release tacrolimus in renal transplant recipients using linear regression analysis and comparison with Bayesian population pharmacokinetics in different cohorts

    by Frank Stifft, Franciscus Vandermeer, Cees Neef, Sander van Kuijk, Maarten H. L. Christiaans

    Purpose Tacrolimus has a narrow therapeutic window. Measuring trough level (C0) as surrogate for drug exposure (AUC) in renal transplant recipients has limitations. Therefore, limited sampling strategies (LSS’s) have been developed. For the newer modified release, once-daily formulation (Tac QD) LSS’s are based on either linear regression analysis (LRA) or population pharmacokinetics with maximum a posteriori Bayesian (MAPB) estimation. The predictive performances of both methods were compared, also to LSS’s as described in literature. Methods LSS’s (maximally three sampling time points) were developed for Tac QD from full 24-h sampling by LRA in 27 Caucasian, stable renal transplant recipients. Performance for accuracy (mean absolute prediction error < 10%) and precision (root mean squared error < 15%) was quantified also after MAPB estimation in two independent groups (early and late post-transplant, n = 12 each). Results LRA determined a single 8 hours post-dose measurement (C8) to fulfil predefined criteria for accuracy (MAPE 3.41%) and precision (RMSE 4.28%). The best LSS contained C2, C8 and C12 for the stable (MAPE 2.42%, RMSE 3.1%) and the early post-transplant group (MAPE 2.46%, RMSE 3.14%). LRA did not include C0 for any LSS, unless it was forced into the model. MAPB estimation showed similar performance. Conclusions In renal transplant patients, sampling in the elimination phase (C8) accurately predicted Tac QD exposure, contrary to C0. The 3-point sampling C2, C8 and C12 had the best performance and is also valid early post-transplant. These LSS’s were similarly predictive with MAPB estimation. Dried blood spot could facilitate late sampling in clinical practice.